Brokers Offer Predictions for Kura Oncology FY2027 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Brookline Capital Management reduced their FY2027 earnings per share (EPS) estimates for shares of Kura Oncology in a research note issued on Tuesday, November 4th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings per share of $2.94 for the year, down from their previous estimate of $2.96. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.90). The firm had revenue of $15.29 million during the quarter, compared to analysts’ expectations of $64.95 million.

Several other equities research analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Sunday, August 17th. Zacks Research downgraded Kura Oncology from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 7th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a research note on Monday, October 20th. Finally, Guggenheim assumed coverage on shares of Kura Oncology in a report on Thursday, September 4th. They set a “neutral” rating on the stock. Ten investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

Kura Oncology Stock Performance

NASDAQ:KURA opened at $9.96 on Wednesday. The stock’s 50 day simple moving average is $9.08 and its two-hundred day simple moving average is $7.26. Kura Oncology has a 1 year low of $5.41 and a 1 year high of $19.73. The company has a market cap of $864.53 million, a price-to-earnings ratio of -4.41 and a beta of 0.35. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.16 and a quick ratio of 6.16.

Insiders Place Their Bets

In other Kura Oncology news, CEO Troy Edward Wilson sold 36,615 shares of the firm’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $8.94, for a total value of $327,338.10. Following the completion of the sale, the chief executive officer owned 246,853 shares of the company’s stock, valued at approximately $2,206,865.82. This trade represents a 12.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Teresa Brophy Bair sold 8,805 shares of Kura Oncology stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $78,716.70. Following the completion of the sale, the insider owned 148,043 shares of the company’s stock, valued at $1,323,504.42. This trade represents a 5.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 78,058 shares of company stock valued at $697,839. 6.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BVF Inc. IL lifted its stake in shares of Kura Oncology by 202.0% during the first quarter. BVF Inc. IL now owns 7,754,129 shares of the company’s stock worth $51,177,000 after buying an additional 5,186,660 shares during the period. Armistice Capital LLC lifted its position in Kura Oncology by 13.3% during the 1st quarter. Armistice Capital LLC now owns 6,572,000 shares of the company’s stock worth $43,375,000 after acquiring an additional 772,000 shares during the period. Vanguard Group Inc. lifted its position in Kura Oncology by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 4,948,235 shares of the company’s stock worth $32,658,000 after acquiring an additional 129,337 shares during the period. EcoR1 Capital LLC lifted its holdings in shares of Kura Oncology by 59.1% during the second quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock worth $24,234,000 after purchasing an additional 1,559,702 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Kura Oncology by 11.7% during the second quarter. Geode Capital Management LLC now owns 2,014,029 shares of the company’s stock worth $11,623,000 after purchasing an additional 211,470 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.